Apogee Therapeutics

About Apogee Therapeutics

Apogee Therapeutics is dedicated to developing best-in-class therapies for immunological and inflammatory disorders. Their mission is to reshape the standard of care for these conditions by exploring treatment options that work better and longer, refusing to settle for 'good enough'. They aim to improve the lives of patients with inflammatory and immune (I&I) diseases through innovative scientific approaches and differentiated therapies.

Products & Services

APG777:A novel antibody therapeutic targeting IL-13, currently in Phase 2 for Atopic Dermatitis and Phase 1 for Asthma and Eosinophilic Esophagitis.

APG279 (APG777 + APG990):A combination therapy targeting IL-13 and OX40L, currently in Phase 1 for Atopic Dermatitis.

Specialties

Immunological Disorders Inflammatory Diseases Antibody Therapeutics Dermatology (Atopic Dermatitis) Respiratory Conditions (Asthma) Gastroenterology (Eosinophilic Esophagitis) inflammatory and immune diseases dermatological conditions respiratory conditions gastroenterological conditions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Strategic Financing (Synthetic Royalty + Senior Debt) T: - FT: Strategic Financing (Synthetic Royalty + Senior Debt)	A: 1300000000 MR: - FA: Up to $1.3 billion FAN: 1300000000	D: 2026-05-27 FD: 2026-05-27	1 investors
2	RT: Public Offering T: - FT: Public Offering	A: 403000000 MR: - FA: approximately $403 million FAN: 403000000	D: 2026-03-26 FD: 2026-03-26	6 investors
3	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 350000000 MR: - FA: 350 million FAN: 350000000	D: 2026-03-24 FD: 2026-03-24	6 investors
4	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 300000000 MR: - FA: $300 million FAN: 300000000	D: 2026-03-23 FD: 2026-03-23	6 investors
5	RT: Public Offering T: - FT: Public Offering	A: 345000000 MR: - FA: $345 million FAN: 345000000	D: 2025-10-10 FD: 2025-10-10	5 investors
6	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 300000000 MR: - FA: $300 million FAN: 300000000	D: 2025-10-08 FD: 2025-10-08	5 investors
7	RT: Public Offering T: - FT: Public Offering	A: 483000000 MR: - FA: approximately $483.0 million FAN: 483000000	D: 2024-03-12 FD: 2024-03-12	5 investors
8	RT: Public Offering T: - FT: Public Offering	A: 420000000 MR: - FA: $420 million FAN: 420000000	D: 2024-03-07 FD: 2024-03-07	5 investors
9	RT: Public Offering T: - FT: Public Offering	A: 350000000 MR: - FA: approximately $350.0 million FAN: 350000000	D: 2024-03-05 FD: 2024-03-05	5 investors
10	RT: IPO T: - FT: IPO	A: 345000000 MR: - FA: approximately $345 million FAN: 345000000	D: 2023-07-18 FD: 2023-07-18	5 investors
11	RT: Initial Public Offering (IPO) T: - FT: Initial Public Offering (IPO)	A: 300000000 MR: - FA: $300 million FAN: 300000000	D: 2023-07-13 FD: 2023-07-13	5 investors

Strategic Financing (Synthetic Royalty + Senior Debt) Latest

2026-05-27

$1.3B

1 investor (Pro only)

Public Offering 2026-03-26

$403.0M

Underwritten Public Offering 2026-03-24

$350.0M

View 10 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael Henderson

Chief Executive Officer

C

Carl Dambkowski

Chief Medical Officer

J

Jane Pritchett Henderson

Chief Financial Officer

R

Rebecca Dabora

Chief Development Officer

M

Matt Batters

Chief Legal Officer

J

Jeff Hartness

Chief Commercial Officer

View 5 more team members with Pro

Unlock Full Team Directory

Recent News